Skip to main content
OpenTrials
Completed

NCT Number: NCT05275556

Gastroenterology Artificial INtelligence System for Detecting Colorectal Polyps (The GAIN Study)

This is a prospective, multicenter, randomized controlled study to evaluate the effect of the Computer-Assisted Detection (CADe) Device on Adenomas Per Colonoscopy and Positive Percent Agreement for routine colonoscopies. The control arm is colonoscopy performed with High Definition White Light Endoscopy (HD-WLE) per standard of care. The intervention arm is colonoscopy performed with HD-WLE per standard of care plus the Computer-Assisted Detection (CADe) Device.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Colon Adenoma Colon Lesion Colon Polyp Colonic Polyps Intestinal Polyps Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Polyps

Age range

45 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Elisha Medical Center, Haifa, Israel

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Scheduled to undergo routine screening (including, but not limited to, FIT/Cologuard positive), routine surveillance (≥3 years as scheduled since last colonoscopy), or diagnostic (symptomatic) colonoscopy with High Definition White Light Endoscopy.
  • Between the ages of 45 and 80 years, inclusive
  • Able and willing to provide written informed consent

Exclusion criteria

  • Self-reported pregnancy
  • Known diagnosis of Colorectal Cancer
  • History of, or referral for, Inflammatory Bowel Disease
  • Previous surgery involving the colon or rectum
  • Referral for known polyp or assessment of post-polypectomy site (i.e. less than 3 years since last colonoscopy).
  • High suspicion or diagnosis of genetic polyposis syndromes, including familial adenomatous polyposis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC), or any other high-risk family history meeting Bethesda guidelines.
  • Referral for overt, symptomatic gastrointestinal bleeding

Treatment and study plan

Computer-Assisted Detection (CADe) Device

Device

The CADe Device uses artificial intelligence to aid in identifying colorectal polyps during High Definition White Light Endoscopy (HD-WLE) based colonoscopies. This device connects the Gastroenterologist's colonoscopy video output source to the main monitor and highlights the regions of interest where the device detects a potential lesion. The CADe Device overlays graphical markers onto video from the endoscope camera and does not perform further processing to the endoscope video signal. This device is not intended to replace clinical decision making.

Primary outcomes

  1. Difference in Adenomas Per Colonoscopy (APC)

    Time frame: Day 1

    Difference in Adenomas Per Colonoscopy (APC) between the control and intervention arm, evaluated for superiority. APC is defined as the average number of histologically confirmed adenomas resected per colonoscopy.

  2. Difference in Positive Percent Agreement (PPA)

    Time frame: Day 1

    Difference in Positive Percent Agreement (PPA) between the control and intervention arm, evaluated for non-inferiority. PPA is defined as the total number of histologically confirmed Clinically Significant Excised Lesions, divided by the total number of excisions.

Secondary outcomes

  1. Adenoma Detection Rate (ADR)

    Time frame: Day 1

    The Adenoma Detection Rate is defined as the number of patients with at least one histologically confirmed adenoma divided by the total number of patients enrolled per study arm.

  2. Number of False Alerts Per Procedure

    Time frame: Day 1

    A false alert is defined as a bounding box that persists on the screen (approximately 2-3 seconds per the judgment of the colonoscopist) that is then determined by the colonoscopist not to contain a polyp. The false alert rate is calculated as the number of false alerts per procedure conducted in the intervention arm of the study.

  3. Mean Withdrawal and Inspection Time (MWT)

    Time frame: Day 1

    The withdrawal time is defined as the time measured from the moment the withdrawal phase of the procedure begins (with the scope in the cecum) to the moment the scope is withdrawn from the patient. The Inspection time measurement will exclude washing and resection, and other peri-resection activity not deemed to be colonic inspection. Inspection times for both the control arm and intervention arm will be calculated retrospectively upon review of the video recordings.

  4. Polyp Detection Rate (PDR)

    Time frame: Day 1

    Polyp detection rate is defined as the proportion of patients with at least one histologically-confirmed polyp detected.

  5. Proximal Adenoma Detection Rate (pADR)

    Time frame: Day 1

    pADR is defined as the percentage of patients with at least one histologically-confirmed adenoma detected in proximal colon.

  6. Flat Adenoma Detection Rate (fADR)

    Time frame: Day 1

    fADR is defined as the percentage of patients with at least one histologically-confirmed non-polypoid adenoma detected.

  7. Serrated Lesions Per Colonoscopy (SLPC)

    Time frame: Day 1

    SLPC is defined as the number of histologically confirmed serrated lesions detected, divided by the total number of colonoscopies.

  8. Serrated Lesions Detection Rate (SLDR)

    Time frame: Day 1

    SLDR is defined as the percentage of patients with at least one histologically confirmed serrated lesion detected.

  9. Adenoma Detection Rate Including Carcinoma (ADR*)

    Time frame: Day 1

    ADR* is defined as ADR, but also includes histologically-confirmed intramucosal carcinoma and adenocarcinoma.

  10. Small Adenoma Detection Rate (sADR)

    Time frame: Day 1

    sADR is defined as the percentage of patients with at least one adenoma 5mm or smaller detected.

  11. Polyps Per Colonoscopy (PPC)

    Time frame: Day 1

    PPC is defined as the total number of histologically-confirmed polyps found divided by the total number of colonoscopies performed, per study arm.

  12. Advanced Adenoma Detection Rate (aADR)

    Time frame: Day 1

    aADR is defined as the percentage of patients with at least one adenoma ≥ 10 mm, or any adenoma < 10 mm, which was either of high-grade dysplasia (HGD) or villous or tubulovillous.

  13. False Positive Rate (FPR)

    Time frame: Day 1

    FPR is defined as the proportion of colorectal lesions resected and biopsied and subsequently not histologically-confirmed to be clinically relevant colorectal polyps (e.g. a pathology finding of normal mucosa, inflammatory tissue, stool or debris, lymphoid aggregates).

Sponsors and collaborators

Lead sponsor

Verily Life Sciences LLC

Industry

Registry information

Acronym: GAIN

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Mar 11, 2022
Registry last updated
Jan 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.